Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice
- PMID: 17913305
- DOI: 10.1016/j.vaccine.2007.08.034
Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice
Abstract
A new fusion peptide CtUBE of cholera toxin B subunit and Helicobacter pylori urease B subunit epitope was expressed in Escherichia coli. With this fusion peptide, an oral liposome vaccine against H. pylori infection was prepared and evaluated in BALB/c mice. Based on the results of urease tests, quantitation of culturable bacteria colonies in mice stomachs and histological identification of gastritis, the mice were protected significantly after intragastric vaccination with this CtUBE liposome vaccine, which increased the content levels of specific anti-urease serum IgG and mucosal IgA for both prophylactic and therapeutic vaccination protocols. These results showed that the fusion peptide CtUBE retained immunogenicity and could be used as antigen in the development of an oral vaccine against H. pylori infection.
Similar articles
-
Immunological features and efficacy of the reconstructed epitope vaccine CtUBE against Helicobacter pylori infection in BALB/c mice model.Appl Microbiol Biotechnol. 2013 Mar;97(6):2367-78. doi: 10.1007/s00253-012-4486-1. Epub 2012 Oct 13. Appl Microbiol Biotechnol. 2013. PMID: 23064457
-
Immunological features and the ability of inhibitory effects on enzymatic activity of an epitope vaccine composed of cholera toxin B subunit and B cell epitope from Helicobacter pylori urease A subunit.Appl Microbiol Biotechnol. 2012 Mar;93(5):1937-45. doi: 10.1007/s00253-011-3726-0. Epub 2011 Dec 2. Appl Microbiol Biotechnol. 2012. PMID: 22134639
-
Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model.Appl Microbiol Biotechnol. 2012 Sep;95(6):1437-44. doi: 10.1007/s00253-012-4122-0. Epub 2012 May 10. Appl Microbiol Biotechnol. 2012. PMID: 22569640
-
Oral immunization against Helicobacter pylori--a future concept.J Gastroenterol. 1998;33 Suppl 10:66-8. J Gastroenterol. 1998. PMID: 9840022 Review.
-
Vaccination against Helicobacter pylori.J Gastroenterol. 1996 Nov;31 Suppl 9:69-74. J Gastroenterol. 1996. PMID: 8959525 Review.
Cited by
-
Targeted nanomedicines for the treatment of Helicobacter pylori infection.Mater Today Bio. 2025 Apr 30;32:101820. doi: 10.1016/j.mtbio.2025.101820. eCollection 2025 Jun. Mater Today Bio. 2025. PMID: 40458694 Free PMC article. Review.
-
Encapsulation of a novel peptide derived from histatin-1 in liposomes against initial enamel caries in vitro and in vivo.Clin Oral Investig. 2023 Dec 26;28(1):35. doi: 10.1007/s00784-023-05465-6. Clin Oral Investig. 2023. PMID: 38147166
-
SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments.Ther Deliv. 2022 Mar;13(3):187-203. doi: 10.4155/tde-2021-0075. Epub 2022 Feb 23. Ther Deliv. 2022. PMID: 35195017 Free PMC article. Review.
-
Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.Pharmaceutics. 2023 Aug 9;15(8):2114. doi: 10.3390/pharmaceutics15082114. Pharmaceutics. 2023. PMID: 37631328 Free PMC article. Review.
-
Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines (Basel). 2025 Jan 27;13(2):126. doi: 10.3390/vaccines13020126. Vaccines (Basel). 2025. PMID: 40006673 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous